Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGD

Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vision updated the TearScience Activator used to deliver the treatment, providing eye care professionals greater treatment precision.

“In my experience, TearScience LipiFlow is a targeted and drug-free solution for treating my patients with MGD, significantly improving ocular surface symptoms, including dry eye symptoms, fluctuating vision and optical aberrations,” said Jerry Hu, MD, Texas Eye & Laser, Fort Worth and Hurst, Texas. “Using the TearScience Activator Clear allows me to see exactly where I’ve positioned the activator before and during treatment, which not only makes treatment more efficient, but also increases comfort for my patients.”

The new design of the TearScience Activator Clear features a single-piece eye cup and translucent design that allows for more efficient and accurate positioning in the eye, giving eye care professionals greater confidence that the activator is delivering heat and pressure evenly across the entire lid. TearScience Activator Clear was also created with the environment in mind, using a redesigned manufacturing process and fewer raw materials than its predecessor.

“TearScience LipiFlow is considered the gold-standard for MGD treatment, but we are always asking ourselves—and our customers—how we can create better outcomes for eye care professionals and their patients, whether through new product innovation or smaller, yet meaningful, enhancements like the TearScience Activator Clear,” said Sajjad Roshanali, Global Business Unit Director, Ocular Surface, Johnson & Johnson Vision. “The design of the new TearScience Activator Clear was developed with the unique needs of eye care professionals in mind, allowing them to ensure the activator is positioned correctly the first time, every time, creating an even better treatment experience for both surgeon and patient.”

TearScience LipiFlow, which has been performed more than 400,000 times worldwide and growing3, uses Vectored Thermal Pulsation (VTP) to treat MGD from the inner lid and help clear gland obstruction, increasing gland function while protecting the cornea and other delicate structures.[1],[2] The treatment is backed by more than 10 years of research[3], including more than 40 peer-reviewed reports and more than 10 prospective randomized and controlled trials.

Research has also shown a positive correlation between TearScience LipiFlow treatment and cataract surgery. Patients who received TearScience LipiFlow treatment prior to cataract surgery reported better outcomes, including significant reduction in reports of postoperative halos, measurable improvements in visual acuity, greater improvement in Meibomian Gland Score, and improved anterior ocular health outcomes.[4]

TearScience Activator Clear is now available for eye care professionals to use as they treat MGD patients with TearScience LipiFlow treatment system in the U.S., Canada, Hong Kong, Chile and Argentina, and will continue to roll out to more countries worldwide throughout 2022.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

**Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.

***Internal data, based on 2020 Analysis of clinical trials

References